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Alzheimer’s disease: the silver tsunami of the 21st 
century
Introduction
Alzheimer’s disease (AD) represents a complex class of debil-
itating brain diseases that mostly affects people aged 65 and 
older. AD is characterized by progressive loss of neurons in 
the hippocampus and cortex, which results in the shrinkage 
of brain. Basically, the brain cells required to process, store 
and retrieve information are killed, which is characteristic 
of a neurodegenerative process (Singh, 2012). It results in 
decline in cognitive and behavioral functions like memory, 
thinking and language skills (O’Brien and Wong, 2010). AD, 
a common form of dementia, is a progressive neurodegener-
ative disorder, which killed half a million people in 2010. AD 
is aptly called as the silver tsunami of the 21st first century. It 
is the sixth leading cause of death in US. It is estimated that 
by 2050, the number of people with AD may nearly triple, 
from 5 million to as many as 16 million, barring the devel-
opment of medical breakthroughs to prevent, slow or stop 
the disease (Xu, 2016). To date, there is no effective cure.  
AD neuropathology is a proteinopathy, which is an out-
come of misfolded proteins. AD is associated with two types 
of abnormal protein deposition in the human brain: (1) 
neurofibrillary tangles (NFTs) containing hyper-phosphory-
lated forms of a microtubule associated protein Tau, and (2) 
accumulation of the plaques of amyloid-beta (Aβ42) peptide 
due to aggregation prone amyloidogenic domains (Hardy, 
2009; Aguzzi and O’Connor, 2010; Fernandez-Funez et al., 
2013; Selkoe and Hardy, 2016).
Generation of Amyloid-beta Plaques in AD  
One of the hallmarks of AD is the accumulation of amyloid 
plaques in the brain. In the healthy brain these plaques are 
not present. The focus of this review is on the accumulation 
of Aβ42 polypeptides formed by the improper cleavage of 
a transmembrane amyloid precursor protein (APP) in the 
brain (Figure 1) (Hardy, 2009; Aguzzi and O’Connor, 2010; 
O’Brien and Wong, 2010; Fernandez-Funez et al., 2013). 
Mutations in the gene encoding for APP have been linked 
to the familial form of AD. APP is proteolytically processed 
in the extracellular and intracellular domains by α and 
then γ-secretase enzymes, which leads to the generation of 
a forty amino acid long polypeptide (Aβ40), which causes 
age-dependent learning defects but no neurodegeneration. 
However, the differential cleavage of APP by the activities 
of β- and γ-secretase enzymes lead to generation of forty 
two amino acid long polypeptide, hence Aβ42 (Figure 1) 
(Hardy, 2009; Aguzzi and O’Connor, 2010; O’Brien and 
Wong, 2010; Fernandez-Funez et al., 2013; Selkoe and Har-
dy, 2016). These extra two amino acids cause the amyloid 
Aβ42 polypeptide to become hydrophobic, resulting in for-
mation of the amyloid plaques. Increased level of the more 
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toxic form of human Aβ42 polypeptide is responsible for 
the neuropathology seen in AD. These plaques disrupt nor-
mal cellular processes through oxidative stress and aberrant 
signaling, resulting in the loss of synaptic activity and death 
of neurons.  
Even though many gene mutations responsible for AD 
have been identified, the detailed genetic signaling mech-
anism(s) responsible for this neurodegeneration and pro-
gression of AD remain indefinable. A great deal of efforts are 
channeled towards discerning the underlying mechanisms 
that induce Aβ42 metabolism and the pathways (e.g., apop-
tosis and autophagy) that trigger neuronal cell death. The 
rationale is to identify the molecular genetic mechanism 
of generation of amyloid (Aβ42) accumulation, which will 
allow (a) development of biomarkers for early detection of 
AD, and (b) development of strategies to prevent accumu-
lation of amyloid plaques, thereby leading to identification 
of drug targets for AD. These insights can lead to a cure or 
better therapeutic strategies for this disease.  
Animal Models for AD 
Clinical trials largely aimed at removing these Aβ42 plaques 
have not yet been efficient. Aβ42 mediated neurodegenera-
tion is a dominant gain-of-function phenotype. Misexpres-
sion of human Aβ42 polypeptides trigger neurodegenera-
tion in traditional mammalian models like the Mouse (Mus 
musculus) as well as in the genetically tractable alternative 
models like zebrafish (Danio rerio), roundworm (Caenor-
habditis elegans), and the fruit fly (Drosophila melanogaster) 
(Iijima and Iijima-Ando, 2008; Moloney et al., 2010; Har-
vey et al., 2011; Singh and Irvine, 2012). It has been seen 
that the primary structures of the Aβ peptide in rats and 
mice differ from their human counterpart at three amino 
acid residues. Furthermore, the complete Aβ-peptide pro-
file produced by the processing of APP in these rodents ex-
hibits major differences in comparison to that of humans. 
In guinea pigs, the rabbit Aβ peptide sequence is identical 
to human but does not present AD pathology spontaneous-
ly. Therefore, alternative animal models for AD have been 
Figure 1 Schematic presentation 
of generation of amyloid-beta 42  
(Aβ42) plaques.
Aβ42 are generated by improper 
cleavage of amyloid precursor pro-
teins (APP). APP a transmembrane 
protein, is cleaved by alpha (α)-sec-
tretase and gamma (γ)-secretase to 
generate forty amino-acid (Aβ40) 
long polypeptide. However, when 
APP is cleaved by beta (β)-secretase 
and gamma (γ)-secretase it gener-
ates forty two amino-acid (Aβ42) 
long polypeptide. Aβ42 polypeptide 
oligomerize to form a plaque. 
Figure 2 Drosophila melanogaster 
(fruit fly) eye model exhibits 
neurodegeneration due to 
accumulation of amyloid-beta 42 
(Aβ42) plaques.
Accumulation of  Aβ42 plaques 
in (A) healthy neuron triggers 
(B) death of  a meuron. (C, D) 
Misexpression of human Aβ42 in 
healthy photoreceptor neurons of 
Drosophila eye using transgenic 
approach causes a (C) wild-type 
adult compound eye to change into 
a (D) highly reduced adult eye due 
to induction of neuronal cell death 
(Tare et al., 2011). 
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developed to understand the mechanism(s) of regulation 
of human Aβ42 protein accumulation, and identification of 
the signaling pathways (e.g., cell death) involved to generate 
insights into the etiology of the disease (Bier, 2005; Singh 
and Irvine, 2012; Moloney et al., 2010; Pandey and Nichols, 
2011; Tare et al., 2011).   
Using an insect Drosophila melanogaster (a.k.a. fruit fly), 
to model human disease is beneficial for many reasons (Bier, 
2005). Most importantly, their entire genome is sequenced, 
and is highly conserved with humans and is significantly less 
redundant (Lenz et al., 2013). Furthermore, they are smaller 
in size and thus can be stored efficiently, are cost effective, 
and can produce two generations in a month (Bier, 2005; 
Singh and Irvine, 2012; Lenz et al., 2013). It makes Dro-
sophila an ideal model for studying age related progressive 
diseases like AD. Several models of AD have been developed 
in Drosophila. These include transgenic flies misexpressing 
human Aβ42, human Aβ40, human APP, BACE, β-secretase 
and Drosophila Psn, FAD (Cauchi and van den Heuvel, 2006; 
Cao et al., 2008; Iijima and Iijima-Ando, 2008; Tare et al., 
2011; Fernandez-Funez et al., 2013). These flies display sev-
eral aspects of clinical AD neuropathology and symptoms 
including the generation of amyloid aggregates, external 
morphological abnormalities, dramatic neuroanatomical 
changes and defects in motor reflex behavior and memory. 
As a proof of concept, treatment with a γ-secretase inhibitor 
was shown to suppress these phenotypes. Drosophila has also 
proved informative as a model of other neurodegenerative 
diseases like Parkinson’s disease, Huntington’s disease, fron-
to-temporal lobar degeneration (FTLD), and amyotrophic 
lateral sclerosis (Bier, 2005; Pandey and Nichols, 2011; Singh 
and Irvine, 2012; Fernandez-Funez et al., 2013).  
Drosophila Eye as Disease Model System  
Drosophila has a fully functional nervous system with a 
structural design that separates specialized functions such 
as vision, olfaction, learning and memory. The Drosophila 
eye develops from a simple monolayer epithelium called the 
eye-antennal imaginal disc which grows during larval stag-
es to form a highly organized compound eye comprised of 
photoreceptor cells, cone cells, and pigment cells (Ready et 
al., 1976; Kumar, 2011; Singh et al., 2012; Kumar, 2013; Tare 
et al., 2013). The precise structure of Drosophila eye makes 
it very sensitive to genetic disruptions/manipulations and it 
can be easily screened using a stereo microscope for pheno-
types generated in the eye field. Thus, Drosophila eye allows 
quick screening of large sample size. The Drosophila model 
has a repertoire of tools that make it indispensable, includ-
ing the ability to express foreign genes along spatio-temporal 
axes that can mimic several important neurodegenerative 
disorders in the compound eye (Bier, 2005; Singh and Irvine, 
2012). Adding to this, the eye is not essential for the viability 
or fertility of the fly. Therefore, the Drosophila eye is an ideal 
organ system to assay the effect of neurodegeneration. Fur-
thermore, the genes involved in eye development are struc-
turally and functionally similar between insects and humans. 
The main advantage of the Drosophila eye is the ability to 
directly visualize the cellular and developmental defects in-
duced by neurodegeneration causing agents.  
We have utilized Drosophila eye to model Aβ42 mediated 
neurodegeneration. Using Gal4/UAS transgenic systems 
(Brand and Perrimon, 1993), we misexpressed human Aβ42 
in the differentiating photoreceptor neurons of the develop-
ing eye (Tare et al., 2011; Moran et al., 2013; Steffensmeier et 
al., 2013; Cutler et al., 2015). It resulted in progressive neu-
rodegenerative phenotype; Cutler et al., 2015 in the Drosoph-
ila eye, which is similar to AD like neuropathology (Figure 
2). However, Drosophila model has some challenges too. In 
comparison to the vertebrates, Drosophila has less complex 
and adaptive immune system. Furthermore, effects of drugs 
on the organism might differ strongly (Prussing et al., 2013). 
Drosophila Model for Genetic Screens
Drosophila model has been extensively used to screen (i) for 
genetic modifiers responsible for onset and manifestation of 
disease and (ii) chemical libraries to look for therapeutic tar-
gets to find cure for the disease. Drosophila model with the 
repertoire of genetic tools allows several different approach-
es like a forward genetic screens, which involve a random 
mutagenesis via chemicals or X-ray radiation and then to 
identify the genes responsible for that phenotype, or reverse 
genetic screen where you mutate a gene and then look for 
the phenotype caused by loss-of-function of that gene (Bier, 
2005; Singh and Irvine, 2012). Forward genetic screens are 
decidedly useful as evidenced by the Nobel prize awarded to 
C. Nüsslein-Volhard, E. Wieschaus and E.B. Lewis in 1995 
for their work in identifying genes involved in early fruit 
fly development (Nusslein-Volhard and Wieschaus, 1980; 
St Johnston, 2002; Lenz et al., 2013). However, mapping of 
mutations using a classical genetic approach can be time 
consuming. The advent of new genetic tools, like single nu-
cleotide polymorphisms (SNPs), has alleviated some of this 
problem in forward genetic screens (Lenz et al., 2013). De-
spite this, few strictly forward genetic screens have been un-
dertaken in an AD background using a Drosophila model. In 
reverse genetic screens, a known gene is disrupted, typically 
utilizing the Gal4/UAS system (Brand and Perrimon, 1993) 
to misexpress a gene or silence a gene using RNA interfer-
ence (RNAi) (Lenz et al., 2013).  
Modifier (also known as enhancer or suppressor) screens 
are highly valuable because they combine the advantages 
of both forward and reverse genetics and carried out using 
easily assayable phenotypes (Lenz et al., 2013; Prussing et al., 
2013). In AD, the Aβ42 neurodegenerative phenotype and 
the rough eye phenotype are easily assayable phenotypes 
(Tare et al., 2011). A Drosophila eye model was established 
where Aβ42 is misexpressed in the developing fly eye results 
in highly reduced neurodegenerative eye (Cao et al., 2008; Ii-
jima and Iijima-Ando, 2008; Tare et al., 2011). We employed 
this model for a small scale modifier screen to look for the 
genetic modifiers which can either enhance/suppress the AD 
eye phenotype by increasing levels of highly conserved sig-
naling pathways (one at a time) (Tare et al., 2011; Moran et 
al., 2013). Using this screen, we have identified the homeotic 
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gene teashirt (tsh), highly conserved apical basal polarity 
marker Crumbs (Crb) (Steffensmeier et al., 2013) as mod-
ifiers of Aβ42 mediated neurodegeneration, making these 
genes as possible target for AD therapies.    
The similar logic was utilized for several high throughput 
screens (HTS) as well as smaller screens to identify genetic 
modifiers of AD. Though many genetic screens for modi-
fiers of Tau induced neurodegeneration have been carried 
out, few large-scale screens have investigated modifiers of 
the Aβ42 neurodegenerative phenotype (Lenz et al., 2013; 
Prussing et al., 2013). Several other earlier genetic screens 
to identify modifiers of the Aβ42 phenotype have resulted 
in a list of potential downstream genetic targets (Cao et al., 
2008). Tan et al. used a screen to identify loss of function 
mutations that either suppressed or enhanced the Aβ42 neu-
rodegenerative phenotype (Tan et al., 2008). Using a IInd 
and IIIrd chromosome deficiency kit they identified a defi-
ciency that uncovers Toll (Tl) suppresses the Aβ42 mediated 
neurodegeneration. Binding of the Toll extracellular domain 
initiates a signaling cascade that eventually leads to activa-
tion the NFκB signaling, a pathway which plays a role in in-
nate immunity and inflammatory responses. Tan et al. (2008) 
identified this inflammatory signaling as playing a key role 
in promoting neurodegenerative processes.  
Ultimately, the goal of these types of genetic screens is to 
identify a particular protein or signaling pathway member, 
which is involved in AD mediated neuropathology that can 
finally be targeted with a chemical compound (Pandey and 
Nichols, 2011). Identification of such a chemical compound is 
typically accomplished by in vitro HTS of a chemical library. 
Once a compound is identified, it is optimized for human 
usage through a series of tests in animal models. This process 
can be inefficient when utilizing traditional in vitro cell cul-
tures or biochemical assays. Furthermore, the paradigm in 
therapeutic treatments has shifted from “one disease-one tar-
get” to an understanding that many diseases result from a va-
riety of factors and interactions. Based on these two problems 
with traditional methods in drug development, Drosophila 
has emerged as a valuable model (Pandey and Nichols, 2011).  
It has already been noted that Drosophila as a model is 
space, time and resource efficient (Lenz et al., 2013). In 
terms of drug development, flies present an advantageous 
supplement or alternative to traditional methods because 
they allow chemical compounds to be tested in vivo in a 
whole organism as opposed to an isolated culture (Pandey 
and Nichols, 2011). Though considerations regarding the 
discrepancies between flies and humans in pharmacokinet-
ics, pharmacodynamics and the toxicity of particular drug 
administered in Drosophila are necessary, overall the model 
has emerged as highly useful in secondary post screening 
validation. Even though other disease systems have utilized 
Drosophila as primary screening models, there are current-
ly no studies which have utilized Drosophila as a primary 
screening model for novel drug discovery in AD (Pandey 
and Nichols, 2011). 
Drug administration typically takes the form of solid 
media to which drugs are added and larvae are allowed to 
grow on. Though Drosophila are useful for HTS, the amount 
of chemicals screened is significantly lower, typically 500 to 
1,000 small molecules per month, than traditional cell cul-
ture assays, which can screen as many as 10,000 small mole-
cules per month. Despite this, screens utilizing flies typically 
result in a higher proportion of hits with therapeutic value. 
In AD models like Drosophila, traditional HTS are frequently 
utilized first to take advantage of their efficiency and iden-
tified small molecules are then tested in flies (Pandey and 
Nichols, 2011).  
One such screen to utilize Drosophila as secondary post 
screening validation identified a particular small molecule 
that inhibited Aβ peptide aggregation. Using a traditional 
HTS based on Aβ42-GFP fusion they identified an inhibitor 
of Aβ aggregation. The most effective inhibitor, D737, was 
administered to transgenic flies with Aβ42 misexpressed in 
neural tissues. They found that not only did the compound 
reduce the toxicity of Aβ42 oligomers, but that it also in-
creased the lifespan of the Aβ42 transgenic flies and their 
locomotive activity (McKoy et al., 2012).  
A recent study examined the neuroprotective effect of 
a flavonoid derivative, 2-(4′ Benzloxyphenyl)-3-hydroxy-
chromen-4-one, on the rough eye phenotype of transgenic 
Aβ42 flies (Singh et al., 2014). The compound was identified 
using an in silico docking approach, then administered to 
transgenic Aβ42 flies to test in vivo. Approximately 70% of 
Aβ42 transgenic flies showed a rescued eye phenotype and 
there was a significant reduction in plaques in Aβ42 trans-
genic larvae (Singh et al., 2014). While this type of post 
screening validation is certainly valuable, other disease mod-
els, including epilepsy and Fragile X syndrome (Stilwell et 
al., 2006), have taken advantage of Drosophila as a primary 
screening tool.  
Conclusion 
Here the vast contribution and potential of the Drosophila 
eye as a model for understanding the cellular and molecular 
mechanisms of neurodegeneration was explored. The eye 
model can be exploited for initial screening of the genetic 
modifiers or chemical inhibitor targets, as well as candidate 
validation. The Drosophila eye as a validation tool in drug 
discovery has gained momentum, which allows identifica-
tion of compounds that would likely be effective in mam-
malian models and humans. Genetic and pharmacological 
screens in the fly eye will serve as a strong screening tool for 
therapeutic approaches in the future. 
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